🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Gilead Sciences' chief commercial officer sells $456,400 in stock

Published 2024/11/07, 23:46
©  Reuters
GILD
-

FOSTER CITY, Calif.—Johanna Mercier, the Chief Commercial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), sold 5,000 shares of the company's common stock on November 6, 2024. The shares were sold at a price of $91.28 each, resulting in a total transaction value of $456,400.

This transaction was conducted under a Rule 10b5-1 trading plan that Mercier adopted earlier this year on April 30. Following the sale, Mercier retains ownership of 73,127 shares in the company.

Gilead Sciences, headquartered in Foster City, California, is a prominent player in the life sciences industry, focusing on biological products.

In other recent news, Gilead Sciences, Inc. revealed its third quarter earnings for 2024. The company's key executives, including Chairman and CEO Daniel O'Day, delivered the remarks during the earnings call. Cindy Perettie, Executive Vice President of Kite, also joined for the question and answer session. The call concluded with a forward-looking outlook but did not disclose specific details about Gilead's performance and future expectations. Supplementary materials related to the earnings are available on the Gilead website for those interested in a more detailed analysis. The company reminded investors about the inherent risks and uncertainties associated with forward-looking statements. This news item forms part of the recent developments concerning Gilead Sciences, Inc.

InvestingPro Insights

Gilead Sciences' recent stock performance and financial metrics provide additional context to Johanna Mercier's share sale. According to InvestingPro data, Gilead's stock is trading near its 52-week high, with a robust 25.06% price total return over the past three months and an impressive 43.11% over the last six months. This strong performance aligns with the timing of Mercier's sale under her pre-established trading plan.

The company's financial health appears solid, with a market capitalization of $121.55 billion and a revenue of $28.3 billion over the last twelve months as of Q3 2024. Gilead's gross profit margin stands at a healthy 77.8%, indicating strong pricing power in its product portfolio.

InvestingPro Tips highlight that Gilead has raised its dividend for 9 consecutive years, which may appeal to income-focused investors. The current dividend yield is 3.36%, offering a steady income stream. Additionally, the company's valuation implies a strong free cash flow yield, suggesting efficient capital management.

It's worth noting that while the stock's recent performance has been strong, the RSI suggests it may be in overbought territory. This could provide context for why insiders like Mercier might choose to sell some shares at current levels.

For investors seeking a deeper understanding of Gilead's prospects, InvestingPro offers 12 additional tips, providing a more comprehensive analysis of the company's financial position and market outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.